Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations

• Main Authors: Bonnet, I. (Author), Boulouard, F. (Author), Brachet, P.-E (Author), Castéra, L. (Author), Coquan, E. (Author), Joly, F. (Author), Krieger, S. (Author), Leconte, A. (Author), Lelaidier, A. (Author), Lequesne, J. (Author), Meriaux, E. (Author), Neviere, Z. (Author), Ricou, A. (Author), Vaur, D. (Author)
• Format: Article
• Language: English
• Published: NLM (Medline) 2022
• Subjects: homologous repair; molecular profile; prostate cancer
• Online Access: View Fulltext in Publisher
• ISBN: 17187729 (ISSN)
• DOI: 10.3390/curroncol29040226

(1) Background: In literature, approximately 20% of mCRPC present somatic DNA damage repair (DDR) gene mutations, and their relationship with response to standard therapies in mCRPC is not well understood. The objective was to evaluate outcomes of mCRPC patients treated with standard therapies according to somatic DDR status. (2) Methods: Eighty-three patients were recruited at Caen Cancer Center (France). Progression-free survival (PFS) after first-line treatment was analyzed according to somatic DDR mutation as primary endpoint. PFS according to first exposure to taxane chemotherapy and PFS2 (time to second event of disease progression) depending on therapeutic sequences were also analyzed. (3) Results: Median first-line PFS was 9.7 months in 33 mutated patients and 8.4 months in 50 non-mutated patients (p = 0.9). PFS of first exposure to taxanes was 8.1 months in mutated patients and 5.7 months in non-mutated patients (p = 0.32) and significantly longer among patients with ATM/BRCA1/BRCA2 mutations compared to the others (10.6 months vs. 5.5 months, p = 0.04). PFS2 was 16.5 months in mutated patients, whatever the sequence, and 11.7 months in non-mutated patients (p = 0.07). The mutated patients treated with chemotherapy followed by NHT had a long median PFS2 (49.8 months). (4) Conclusions: mCRPC patients with BRCA1/2 and ATM benefit from standard therapies, with a long response to taxanes.